本文關(guān)鍵詞： 苯甲地鈉銨(苦精) 哮喘 苦味受體 鈣結(jié)合蛋白SA 氣道黏液　出處：《醫(yī)學(xué)研究生學(xué)報(bào)》2017年02期 　論文類(lèi)型：期刊論文

【摘要】：目的研究發(fā)現(xiàn)在人體肺部存在苦味受體,目前關(guān)于苦味受體激動(dòng)劑與氣道黏液分泌的研究報(bào)道較少。探討肺部苦味受體激動(dòng)劑苯甲地鈉銨(苦精)對(duì)哮喘小鼠氣道中鈣結(jié)合蛋白S100A9水平和氣道中黏液分泌的影響。方法將健康清潔型雄性BALB/c小鼠按隨機(jī)數(shù)字表分成5組:正常對(duì)照組,慢性哮喘組,苦精干預(yù)1、2、3周組,每組8只。除正常對(duì)照組外,其余組小鼠于第1天和第15天分別腹腔注射0.2 m L氫氧化鋁混懸液[含100μg OVA,1 mg Al(OH)3)]致敏�？嗑深A(yù)1、2、3周組小鼠分別從第10、9、8周起在激發(fā)的基礎(chǔ)上吸入800μg苦精1、2、3周。ELISA法及免疫組化法檢測(cè)肺泡灌洗液(BALF)上清、肺組織中S100A9蛋白水平,糖原PAS染色及實(shí)時(shí)定量PCR顯示氣道杯狀細(xì)胞數(shù)量、黏液性物質(zhì)及黏蛋白MUC5AC的含量。結(jié)果與正常對(duì)照組BALF上清中S100A9水平[(6.19±0.61)ng/m L]比較,慢性哮喘組以及苦精干預(yù)1、2周組[(11.89±0.77)、(10.69±0.79)、(9.49±0.99)ng/m L]明顯升高(P0.05);苦精干預(yù)1、2、3周組較慢性哮喘組降低(P0.05)。與正常對(duì)照組比較,免疫組化染色顯示慢性哮喘組氣道上皮細(xì)胞中S100A9高表達(dá),苦精干預(yù)1、2、3周后,氣道上皮細(xì)胞中S100A9表達(dá)隨苦精干預(yù)時(shí)間增加而減少。糖原PAS染色顯示,與正常對(duì)照組比較,慢性哮喘組氣道上皮杯狀細(xì)胞增生,黏液過(guò)度分泌(P0.01)。與慢性哮喘組比較,苦精干預(yù)1、2、3周組杯狀細(xì)胞數(shù)量、黏液分泌量隨苦精干預(yù)時(shí)間的增加而減少。與正常對(duì)照組比較,慢性哮喘組以及苦精干預(yù)1、2周組肺組織中黏蛋白MUC5AC mRNA表達(dá)增高,差異有統(tǒng)計(jì)學(xué)意義(P0.05),與慢性哮喘組比較,苦精干預(yù)后,MUC5AC的mRNA表達(dá)降低,并隨苦精干預(yù)時(shí)間的增加而降低,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論苦精下調(diào)小鼠杯狀細(xì)胞的黏液分泌可能與上皮細(xì)胞鈣結(jié)合蛋白S100A9有關(guān)。
[Abstract]:Objective to study the existence of bitter receptors in human lungs. There are few reports about bitter receptor agonists and airway mucus secretion. To explore the effects of pulmonary bitter receptor agonist benzodimethylammonium (bitter essence) on the levels of calcium binding protein S100A9 in the airway and mucus secretion in the airway of asthmatic mice. Methods healthy and clean male BALB/c mice were randomly divided into 5 groups: normal control group. In the chronic asthma group, 8 rats in each group were treated with bitter extract for 3 weeks, except for the normal control group. The mice in the other group were sensitized by intraperitoneal injection of 0.2 mL aluminum hydroxide suspension (containing 100 渭 g OVAX 1 mg Albumin 3) on day 1 and day 15, respectively. And immunohistochemical method was used to detect the supernatant of alveolar lavage fluid (BALF). The levels of S100A9 protein in lung tissue, glycogen PAS staining and real-time quantitative PCR showed the number of goblet cells, mucin and mucin MUC5AC in the airway. The results were compared with those in the normal control group (6.19 鹵0.61g / mL). The expression of S100A9 in airway epithelial cells of chronic asthma group was significantly higher than that of chronic asthma group after 1 ~ 2 weeks of treatment [11.89 鹵0.77 ~ 10.69 鹵0.79 ng / mL], and the expression of S100A9 in airway epithelial cells of chronic asthma group was significantly higher than that of chronic asthma group at 3 weeks after treatment with bitter spermatine for 1 ~ 2 ~ 2 weeks. Compared with normal control group, the expression of S100A9 in airway epithelial cells in chronic asthma group was significantly higher than that in control group, and the expression of S100A9 in airway epithelial cells in chronic asthma group was significantly higher than that in control group. The expression of S100A9 in airway epithelial cells decreased with the increase of the time of intervention. Glycogen PAS staining showed that, compared with the normal control group, the airway epithelial goblet cells proliferated in chronic asthma group. Compared with the chronic asthma group, the number of goblet cells in the group treated with bitter spermatine for 3 weeks was decreased with the increase of the time of the intervention. Compared with the normal control group, the number of goblet cells decreased with the increase of the time of the treatment. The expression of mucin MUC5AC mRNA in the lung tissue of chronic asthma group and the group treated with bitter essence for 1 to 2 weeks was increased, the difference was statistically significant (P 0.05). Compared with the group of chronic asthma, the expression of MUC5AC mRNA in bitter dry prognosis was lower than that in chronic asthma group, and the expression of MUC5AC decreased with the increase of the time of intervention. Conclusion the down-regulation of mouse goblet cell mucus secretion may be related to the calcium binding protein S100A9.
【作者單位】： 濰坊醫(yī)學(xué)院臨床醫(yī)學(xué)院;濰坊醫(yī)學(xué)院附屬醫(yī)院呼吸內(nèi)科;
【分類(lèi)號(hào)】：R562.25

【參考文獻(xiàn)】

相關(guān)期刊論文 前4條

1 吳海蘭;辛?xí)苑?;上皮間充質(zhì)轉(zhuǎn)化與慢性阻塞性肺疾病的氣道重塑[J];醫(yī)學(xué)研究生學(xué)報(bào);2015年09期

2 方麗萍;趙明;張鵬鵬;吳潔;戴偉;辛?xí)苑?;難治性哮喘患者血清腫瘤壞死因子-α的表達(dá)及其與肺功能和氣道炎癥的關(guān)系[J];醫(yī)學(xué)研究生學(xué)報(bào);2014年01期

3 祖圓;劉松;;咳嗽變異性哮喘[J];醫(yī)學(xué)研究生學(xué)報(bào);2013年04期

4 辛?xí)苑?趙明;張方;李子玲;宋勇;施毅;;重度支氣管哮喘患者誘導(dǎo)痰中白細(xì)胞介素-17水平及其與氣道炎癥和氣流受限的關(guān)系[J];醫(yī)學(xué)研究生學(xué)報(bào);2008年08期

【共引文獻(xiàn)】

相關(guān)期刊論文 前10條

1 閆珊;程麗;趙曉寧;黃軼民;劉靜靜;高福生;;苦精對(duì)哮喘小鼠氣道中鈣結(jié)合蛋白S100A9及氣道黏液分泌的影響[J];醫(yī)學(xué)研究生學(xué)報(bào);2017年02期

2 石海;;血清腫瘤壞死因子-α、超敏C反應(yīng)蛋白在支氣管哮喘病情發(fā)生發(fā)展中的表達(dá)及意義[J];中外醫(yī)學(xué)研究;2017年03期

3 王利玲;吳強(qiáng)鵬;程黎;;抗菌肽LL-37激活嗜酸性粒細(xì)胞釋放炎性遞質(zhì)對(duì)哮喘的發(fā)病機(jī)制研究[J];醫(yī)學(xué)研究生學(xué)報(bào);2017年01期

4 尹麗明;陳紅華;馮曉英;;細(xì)菌溶解產(chǎn)物聯(lián)合布地奈德治療兒童反復(fù)呼吸道感染支氣管炎的臨床研究[J];現(xiàn)代藥物與臨床;2016年08期

5 徐鋒;韓紀(jì)昌;張雅軍;劉笑春;戚冠斌;;阿奇霉素對(duì)難治性哮喘患者肺功能及氣道炎癥的療效觀察[J];中國(guó)現(xiàn)代藥物應(yīng)用;2016年16期

6 葉巍;夏風(fēng)杰;姚瑤;曹謙;閆峰;黃振平;;機(jī)械牽拉誘導(dǎo)人RPE細(xì)胞IL-8分泌及其對(duì)PI3K/AKT通路的影響[J];現(xiàn)代生物醫(yī)學(xué)進(jìn)展;2016年22期

7 張莉;趙玉仙;邸金娜;胡泊;左壯;;白介素-4和IgE在咳嗽變異性哮喘診斷中的價(jià)值分析[J];臨床醫(yī)藥文獻(xiàn)電子雜志;2016年26期

8 林亞發(fā);程宏寧;;氨溴索聯(lián)合孟魯斯特鈉治療難治性哮喘的效果觀察[J];醫(yī)學(xué)綜述;2016年15期

9 賀元;廖明芳;曲樂(lè)豐;;YKL-40在炎癥性疾病中的作用及其信號(hào)通路研究進(jìn)展[J];醫(yī)學(xué)研究生學(xué)報(bào);2016年08期

10 劉焰;;疏金利肺湯輔助沙美特羅/氟替卡松吸入治療咳嗽變異性哮喘療效觀察[J];現(xiàn)代中西醫(yī)結(jié)合雜志;2016年19期

【二級(jí)參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 Caroline Moyret-Lalle;Emmanuelle Ruiz;Alain Puisieux;;Epithelial-mesenchymal transition transcription factors and mi RNAs: “Plastic surgeons” of breast cancer[J];World Journal of Clinical Oncology;2014年03期

2 王海燕;何創(chuàng);肖建斌;高巨;;轉(zhuǎn)化生長(zhǎng)因子-β_1抗體對(duì)肺損傷纖維化大鼠細(xì)胞外基質(zhì)重建紊亂的調(diào)控[J];醫(yī)學(xué)研究生學(xué)報(bào);2014年04期

3 高璐;呂剛;孫凱;蔣國(guó)成;張長(zhǎng)松;李蓉;衛(wèi)立辛;;分化抑制因子1通過(guò)誘導(dǎo)上皮間質(zhì)轉(zhuǎn)化促進(jìn)肝癌HepG2細(xì)胞的侵襲性[J];醫(yī)學(xué)研究生學(xué)報(bào);2013年12期

4 祖圓;劉松;;咳嗽變異性哮喘[J];醫(yī)學(xué)研究生學(xué)報(bào);2013年04期

5 劉唐娟;孔晉亮;陳一強(qiáng);;難治性哮喘診斷及病因認(rèn)識(shí)進(jìn)展[J];中華哮喘雜志(電子版);2012年02期

6 ，

本文編號(hào)：1510074